Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lecanemab for Moderate to Severe Alzheimer's Disease (Ningbo Lihuili Hospital)
ChiCTR2500102030Phase 4Not yet recruiting
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of lecanemab in Alzheimer's disease (AD) (2 arms), sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoints: Brief Psychological Status Scale score at 12 months, Montreal Cognitive Assessment (MoCA) score and 2 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2500102030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102030.